Stability of a formalin-inactivated Rift Valley fever vaccine: Evaluation of a vaccination campaign for cattle in Mozambique

Vaccine

Volumn 30, Issue 46, 2012, Pages 6534-6540

  Lagerqvist, N ^a,b   Moiane, B ^b,c   Bucht, G ^d   Fafetine, J ^c   Paweska, J T ^e   Lundkvist, å ^a,b   Falk, K I ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^d SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

^e NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

Bovine; Formalin inactivated vaccine; Mozambique; Rift Valley fever; Virus

Indexed keywords

FORMALDEHYDE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; RIFT VALLEY FEVER VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CATTLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STABILITY; DRUG STORAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LOW TEMPERATURE; MALE; MOZAMBIQUE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLAQUE REDUCTION NEUTRALIZATION TEST; PRIORITY JOURNAL; RIFT VALLEY FEVER; SERODIAGNOSIS; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CATTLE; CATTLE DISEASES; DRUG STABILITY; FEMALE; FORMALDEHYDE; MALE; MOZAMBIQUE; NEUTRALIZATION TESTS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; TEMPERATURE; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84867018746     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.052     Document Type: Article

References (36)

1. Daubney R., Hudson J.R., Garnham P.C. Enzootic hepatitis or Rift Valley fever: an undescribed disease of sheep, cattle and man from East Africa. J Pathol Bacteriol 1931, 34:545-579.
2. Bouloy M., Weber F. Molecular biology of Rift Valley fever virus. Open Virol J 2010, 4:8-14.
3. Paweska J.T., Jansen van Vuren P., Swanepoel R. Validation of an indirect ELISA based on a recombinant nucleocapsid protein of Rift Valley fever virus for the detection of IgG antibody in humans. J Virol Methods 2007, 146:119-124.
4. Paweska J.T., van Vuren P.J., Kemp A., Buss P., Bengis R.G., Gakuya F., et al. Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo. Vet Microbiol 2008, 127:21-28.
5. Besselaar T.G., Blackburn N.K. The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins. Arch Virol 1992, 125:239-250.
6. Bicout D.J., Sabatier P. Mapping Rift Valley fever vectors and prevalence using rainfall variations. Vector Borne Zoonotic Dis 2004, 4:33-42.
7. Davies F.G., Linthicum K.J., James A.D. Rainfall and epizootic Rift Valley fever. Bull World Health Organ 1985, 63:941-943.
8. Ikegami T., Makino S. The pathogenesis of Rift Valley fever. Viruses 2011, 3:493-519.
9. Swanepoel R., Coetzer J.A.W. Rift Valley fever. Infectious diseases of livestock 1994, 688-717. Oxford University Press, Cape Town. J.A.W. Coetzer, G.R. Thomson, R.C. Tustin (Eds.).
10. Rich K.M., Wanyoike F. An assessment of the regional and national socio-economic impacts of the 2007 Rift Valley fever outbreak in Kenya. Am J Trop Med Hyg 2010, 83:52-57.
11. Bouloy M., Flick R. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res 2009, 84:101-118.
12. Dungu B., Louw I., Lubisi A., Hunter P., von Teichman B.F., Bouloy M. Evaluation of the efficacy and safety of the Rift Valley fever Clone 13 vaccine in sheep. Vaccine 2010, 28:4581-4587.
13. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 1997, 58:1104-1109.
14. Smithburn K.C. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 1949, 30:1-16.
15. Barnard B.J., Botha M.J. An inactivated Rift Valley fever vaccine. J S Afr Vet Assoc 1977, 48:45-48.
16. Botros B., Omar A., Elian K., Mohamed G., Soliman A., Salib A., et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 2006, 78:787-791.
17. Kamal S.A. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J 2009, 6:94.
18. The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting. Bull World Health Organ 1983, 61:261-268.
19. Nderitu L., Lee J.S., Omolo J., Omulo S., O'Guinn M.L., Hightower A., et al. Sequential Rift Valley fever outbreaks in eastern Africa caused by multiple lineages of the virus. J Infect Dis 2011, 203:655-665.
20. Perez A.M., Medanic R.C., Thurmond M.C. Rift Valley fever outbreaks in South Africa. Vet Rec 2010, 166:798.
21. Valadão F.G. Nota prévia sobre a ocorrência de uma nova doença em Moçambique-A febre do Vale de Rift. Vet Moçamb Lourenço Marques 1969, 2:13-20.
22. Niklasson B., Liljestrand J., Bergstrom S., Peters C.J. Rift Valley fever: a sero-epidemiological survey among pregnant women in Mozambique. Epidemiol Infect 1987, 99:517-522.
23. Direcção Nacional de Pecuária Ministério de Agrecultura e Desenvolvimento Rural. Relatório anual 2001. Maputo; 2002. p. 32-3.
24. Meegan J. The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizotic and virological studies. Trans R Soc Trop Med Hyg 1979, 73:618-623.
25. Sall A.A., Zanotto P.M., Sene O.K., Zeller H.G., Digoutte J.P., Thiongane Y., et al. Genetic reassortment of Rift Valley fever virus in nature. J Virol 1999, 73:8196-8200.
26. Lindkvist M., Lahti K., Lilliehook B., Holmstrom A., Ahlm C., Bucht G., et al. Cross-reactive immune responses in mice after genetic vaccination with cDNA encoding hantavirus nucleocapsid proteins. Vaccine 2007, 25:1690-1699.
27. Jansen van Vuren P., Potgieter A.C., Paweska J.T., van Dijk A.A. Preparation and evaluation of a recombinant Rift Valley fever virus N protein for the detection of IgG and IgM antibodies in humans and animals by indirect ELISA. J Virol Methods 2007, 140:106-114.
28. Frey A., Di Canzio J., Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998, 221:35-41.
29. Direcção Nacional de Gestão Ambiental, Ministério Para a Coordenação da Acção Ambiental. Avaliação da vulnerabilidade as mudanças climáticas estratégias de adaptação. Maputo; 2005. p. 7-8.
30. McIntosh B.M. Rift Valley fever, 1. Vector studies in the field. J S Afr Vet Med Assoc 1972, 43:391-395.
31. Direcção Nacional de Pecuária, Ministério de Agrecultura e Desenvolvimento Rural. Relatório anual 2002. Maputo; 2003. p. 45.
32. Barnard B.J. Rift Valley fever vaccine - antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc 1979, 50:155-157.
33. Cêtre-Sossah C., Billecocq A., Lancelot R., Defernez C., Favre J., Bouloy M., et al. Evaluation of a commercial competitive ELISA for the detection of antibodies to Rift Valley fever virus in sera of domestic ruminants in France. Prev Vet Med 2009, 90:146-149.
34. Brandau D.T., Jones L.S., Wiethoff C.M., Rexroad J., Middaugh C.R. Thermal stability of vaccines. J Pharm Sci 2003, 92:218-231.
35. Randall R., Binn L.N., Harrison V.R. Immunization against Rift Valley fever virus. Studies on the immunogenicity of lyophilized formalin-inactivated vaccine. J Immunol 1964, 93:293-299.
36. Rashid A., Rasheed K., Akhtar M. Factors influencing vaccine efficacy - a general review. J Anim Plant Sci 2009, 19:22-25.